Mount Laurel Township

This study aims to collect prospective safety and effectiveness data for the C-Brace System, a microprocessor-controlled knee ankle foot orthosis, following standard care practices. The research focuses on patients with lower extremity pareses who are fitted with the C-Brace device. The goal is to better understand how the C-Brace influences walking speed, balance, risk of falling, and confidence in balance over time. The C-Brace is a custom-made device with thigh, calf, and foot components connected by an ankle joint or spring element. It uses sensors to continuously monitor knee joint movement and walking phases, adjusting hydraulic resistance and knee motion accordingly. Patients enrolled in the registry will undergo baseline evaluation, fitting, training or therapy sessions, and follow-up visits at 6, 12, 24, and 36 months after fitting. Participants will be assessed through various tests including timed walk tests, balance confidence scores, and mobility assessments at different intervals. The study also tracks falls related to device use and changes in activity levels with an activity tracker. Data collected will help characterize the safety and functional impact of the C-Brace over three years of follow-up.

Researchers are comparing two treatment approaches for patients with stage II to IIIB non-small cell lung cancer (NSCLC) that can be surgically removed. The study evaluates whether giving standard therapy both before and after surgery (perioperative) is more effective than giving it only after surgery (adjuvant). The trial is phase III and aims to understand which approach leads to better survival and fewer complications in patients with resectable lung cancer. Participants are randomly assigned to one of two treatment groups. In the first group, patients have surgery within 28 days of joining the study, followed by up to four cycles of platinum-based chemotherapy and up to one year of immunotherapy if the cancer does not progress or cause unacceptable side effects. In the second group, patients receive chemotherapy combined with immunotherapy before surgery, then undergo surgery, and continue immunotherapy after surgery for up to one year under similar conditions. Throughout the study, patients may have CT scans, and possibly MRI or PET/CT scans at the start. During the trial, researchers will monitor patients closely over time, including follow-up visits every six months for up to 10 years after treatment ends. They will assess outcomes such as survival without events like cancer recurrence or progression, overall survival, rates of surgery and complete tumor removal, side effects leading to treatment stops or hospitalizations, and the body's response to treatment. This comprehensive monitoring helps evaluate the benefits and risks of each treatment approach.

Researchers are evaluating the outcomes of two treatments for lumbar spinal stenosis with neurogenic claudication (LSS with NC) in Medicare beneficiaries. This observational study compares the rates of surgical and minimally invasive interventions, as well as any harms, occurring within 24 months after receiving either the MILD procedure or Interspinous Process Decompression (IPD). The study uses Medicare claims data starting from patients treated on or after January 1, 2017, and continues enrollment until the sponsor stops it. The study groups include Medicare patients who underwent the MILD procedure, which involves a partial decompression performed under fluoroscopic image guidance through the removal of tissue and bone at the symptomatic spinal level. The control group consists of Medicare patients treated with Interspinous Process Decompression during the same enrollment period. Both groups are monitored for reoperation and harms for 24 months following their initial treatment. Participants are included based on Medicare claims with the study's NCT number, which automatically enrolls them without requiring prior consent. Researchers will analyze Medicare claims data to track surgical or minimally invasive interventions and any complications related to the initial procedure over two years. The study does not involve direct patient visits or interventions and is exempt from Institutional Review Board oversight. The total follow-up duration for outcome measurement is 24 months after the index procedure.

This trial investigates treatments for chronic lateral epicondylitis, also known as tennis elbow, which can cause pain and interfere with daily activities and work. The study aims to compare two treatment methods to determine if one is better than the other for relieving symptoms and improving function. It is a randomized controlled trial led by Sean Mc Millan, focusing on patients who have had symptoms for at least six months and have tried other treatments without success. Participants will be randomly assigned to receive either the Ultrasound-guided Percutaneous Tenotomy Technique (Tenex procedure) or Open Surgical Debridement. The Tenex procedure uses a special needle and ultrasonic energy to remove damaged tissue under local anesthesia in the surgeon's office. Open Surgical Debridement is a traditional surgery involving an incision to remove damaged tissue under anesthesia in a surgery center. Both procedures target the damaged tendon area causing pain. During the study, participants will have follow-up visits at 3 weeks, 6 weeks, 3 months, 6 months, and 12 months after treatment. At each visit, their progress will be monitored through physical exams and questionnaires. The main outcome measured is the comparison of complications and functional results between the two treatments. The total participation period includes the initial screening and one year of follow-up to assess recovery and treatment effects.

Researchers are evaluating whether adding stereotactic ablative radiotherapy (SABR) to standard immunotherapy improves outcomes for patients with metastatic renal cell carcinoma that cannot be surgically removed. This phase II trial compares the combination of SABR with immunotherapy against immunotherapy alone. The study focuses on patients with unresected kidney cancer that has spread to other parts of the body and is not recommended for immediate surgery. Participants are randomly assigned to one of two groups. One group receives immunotherapy drugs such as nivolumab, ipilimumab, pembrolizumab, avelumab, axitinib, cabozantinib, or lenvatinib, administered intravenously or orally according to the doctor's choice. The other group receives the same immunotherapy combined with SABR delivered on three separate days over one to three weeks. Imaging scans like CT or MRI and bone scans are performed during the trial to monitor disease and treatment effects. Throughout the study, patients undergo regular imaging and blood tests to assess tumor response and safety. The main outcome measured is nephrectomy and radiographic progression-free survival over up to eight years. Secondary outcomes include response rates, overall survival, treatment tolerability, and the need for additional therapies. After treatment, patients are followed every six months for five years, then annually for three years to monitor long-term effects and outcomes.